Sarah Karlin-Smith
Xconomy
Washington, DC, United States
Contact Sarah
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Sarah:
Xconomy: Moderna, Pfizer Protocols May Make COVID Vaccines Hard to Compare
It will be difficult to compare Moderna, Inc. and Pfizer Inc.’s coronavirus vaccines based on their Phase 3 study designs, some vaccines experts said. → Read More
Xconomy: Moderna: Speed of COVID 19 Vaccine Hinges On Enrolling Right Patients
Fast enrollment of the right patient populations will be critical to quickly conducting Phase III trials of COVID-19 vaccines and this will likely mean → Read More
Xconomy: Antibiotic Development: HHS Not Yet Sold on “Pull” Incentives
The US Health and Human Services agency isn’t ready to go all in on “pull” incentives to encourage the development of new antibiotics, the agency → Read More
Coronavirus emergency bill held up over vaccine cost concerns
“Our Republican friends don't want to see the kinds of limitations that we want to see," Senate Minority Leader Sen. Chuck Schumer said after a briefing with members of the White House’s coronavirus task force. | Sarah Silbiger/Getty Images An emergency funding bill to respond to coronavirus is being held up by a dispute about overpaying for tests, treatments and vaccines. Senate Minority Leader… → Read More
FDA: No drug shortages reported because of coronavirus but situation 'fluid'
Even before coronavirus, lawmakers were questioning U.S. reliance on China's medical industry. → Read More
Pelosi's new drug plan pressures Trump on campaign pledge
The plan is less ambitious than what many progressives would like. → Read More
Pelosi steams ahead with drug pricing plan amid liberal angst
The speaker is running into resistance on the left on a top priority for the party. → Read More
Democrats favor righteous rage, GOP the safer bet in Purdue opioids settlement
The vitriol reflects the Sacklers' position as the poster children of drug industry malfeasance. → Read More
Pelosi tries to split Trump, Republicans over drug pricing
The six-page proposal that surfaced Monday is more progressive than many expected. → Read More
Cancer specialist is frontrunner for FDA commissioner
Stephen Hahn is in line to be nominated to head the agency within the next several weeks, pending completion of a background check. → Read More
Trump’s bid to wipe out AIDS will take more than a pill
People who are still at risk have complex, unmet social needs. → Read More
Trump touts Democratic playbook in crackdown on drug costs
Republicans are being pulled to the left by the White House embrace of Democrats' ideas. → Read More
Killing Obamacare kills Trump’s health agenda, too
President Donald Trump's renewed push to gut Obamacare could sabotage the rest of his health agenda. → Read More
FDA moves on vaping, drugs and food at risk with chief’s departure
Scott Gottlieb’s legacy is in limbo. → Read More
‘It’s finally pharma’s turn’: Drug CEOs face Capitol Hill reckoning
Seven drugmakers will be grilled over high prices at a hearing this week, in what could be a watershed moment for the industry. → Read More
What a medical school on a Rwandan hilltop can teach the United States
Doctors learn to treat patients without all the high-tech tools — and fairness and access are crucial. → Read More
Warren bill would get feds into generic drug manufacturing
The Massachusetts Democrat, who's likely running for president in 2020, joins a recent wave of Senate legislation aimed at the pharmaceutical industry. → Read More
Why Trump still needs Obamacare
To bring down drug prices and fight opioids, the White House uses provisions of the health law it constantly attacks. → Read More
The Bernie Sanders-Trump mind meld on drug costs
The bill, sponsored by Sen. Bernie Sanders and Rep. Ro Khanna, is sure to face stiff opposition from the drug industry. → Read More
Pfizer raises drug prices again, rebuking Trump
Pfizer's new price increases, which take effect Jan. 15, will apply to 10 percent of its portfolio, the company said. → Read More